Researchers report that circulating extracellular vesicle proteins can both predict outcomes and directly interfere with CLDN18.2 CAR T-cell and antibody therapies in gastrointestinal cancers. The study identifies a vesicle protein effect that undermines cell and antibody targeting, highlighting an additional layer of tumor- and host-derived resistance beyond antigen expression levels. This adds an actionable dimension to biomarker development: profiling vesicle proteins could help anticipate response and tailor therapy selection. It also suggests that drug mechanism can be neutralized by decoy or competitive binding interactions carried in circulation. For clinical teams, the near-term implication is more complicated predictive workup for CLDN18.2 programs, potentially requiring assays that capture extracellular vesicle cargo rather than only tissue antigen staining. For the pipeline, the findings encourage new combination or engineering strategies designed to reduce vesicle-mediated interference, whether by modifying binding domains, altering dosing schedules, or targeting vesicle biology.